A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Patients With Locally Advanced or Metastatic Solid Tumours
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and
pharmacokinetics of the combination of MOXR0916 and Atezolizumab with or without bevacizumab
in participants with locally advanced, recurrent, or metastatic incurable solid malignancy
that has progressed after available standard therapy, or for which standard therapy has
proven to be ineffective or intolerable, or is considered inappropriate; or for which a
clinical trial of an investigational agent is a recognized standard of care.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society